#MedSky🧪#IDSky #ImmunoSky #MolecularBiology Recap : Although some #PI3Kinhibitors have been approved for clinical use, most of these compounds have failed to meet the initial high expectations and their utility in #cancertreatment is limited by systemic toxicity and/or tumor drug resistance .
November 3, 2024 at 5:26 AM
#MedSky🧪#IDSky #ImmunoSky #MolecularBiology Recap : Although some #PI3Kinhibitors have been approved for clinical use, most of these compounds have failed to meet the initial high expectations and their utility in #cancertreatment is limited by systemic toxicity and/or tumor drug resistance .
This study identifies four molecular subtypes within HR+/HER2+ #BreastCancer and shows how their distinct biology guides tailored therapies, from intensified #antiHER2 regimens to ER–HER2 targeting, ADCs, #immunotherapy, and #PI3Kinhibitors.
#OpenAccess #STTT: doi.org/10.1038/s413...
#OpenAccess #STTT: doi.org/10.1038/s413...
December 11, 2025 at 10:40 AM
This study identifies four molecular subtypes within HR+/HER2+ #BreastCancer and shows how their distinct biology guides tailored therapies, from intensified #antiHER2 regimens to ER–HER2 targeting, ADCs, #immunotherapy, and #PI3Kinhibitors.
#OpenAccess #STTT: doi.org/10.1038/s413...
#OpenAccess #STTT: doi.org/10.1038/s413...
How soy and gut microbes alter cancer treatment results www.news-medical.net/news/2025060... #cancer #microbiome #phytochemicals #PI3Kinhibitors #drugmetabolism #soy #precisionmedicine #oncology #dieta #cancer @cellpress.bsky.social
How soy and gut microbes alter cancer treatment results
Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness of PI3K inhibitors in cancer therapy. The study reveals that dietary compon...
www.news-medical.net
June 3, 2025 at 3:26 AM
How soy and gut microbes alter cancer treatment results www.news-medical.net/news/2025060... #cancer #microbiome #phytochemicals #PI3Kinhibitors #drugmetabolism #soy #precisionmedicine #oncology #dieta #cancer @cellpress.bsky.social